摘要:
A method of treating a mammal with an adiponectin mediated disorder comprising administering a therapeutically effective amount of an adiponectin variant with at least a 3-fold increased solubility relative to residues 110-244 of human adiponectin.
摘要:
An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the adiponectin variant is not glycosylated, the adiponectin variant does not have residues 1-100 relative to human adiponectin, and wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.
摘要:
An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.
摘要:
A composition comprising an adiponectin variant at a concentration of at least 2.0 mg/mL, and a pharmaceutically acceptable carrier, wherein less than 20% of said adiponectin variant would aggregate after storage at 4° C. for one week in 10 mM PO4, 150 mM NaCl buffer.
摘要翻译:包含浓度为至少2.0mg / mL的脂联素变体的组合物和药学上可接受的载体,其中小于20%的所述脂联素变体在4℃下在10mM PO4,150中保存一周后将聚集 mM NaCl缓冲液。
摘要:
1. A composition comprising an adiponectin variant at a concentration of at least 2.0 mg/mL, and a pharmaceutically acceptable carrier, wherein less than 20% of said adiponectin variant would aggregate after storage at 4° C. for one week in 10 mM PO4, 150 mM NaCl buffer.
摘要:
The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.
摘要:
The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.
摘要:
An adiponectin variant with at least a 3-fold increased solubility relative to residues 110-244 of human adiponectin, wherein the adiponectin variant has at least one covalently attached non-peptide moiety at at least one position selected from the group consisting of: A108, Y109, S146, D179, E220, R221, and L224, relative to human adiponectin
摘要:
A method of treating a mammal with an adiponectin mediated disorder comprising administering a therapeutically effective amount of an adiponectin variant with at least a 3-fold increased solubility relative to residues 110-244 of human adiponectin
摘要:
Adiponectin variants comprising one or more amino acid modifications to corresponding wild-type adiponectins at positions having predetermined hydrophobicity, predetermined polarity, predetermined electrostatic potential, Met, aromatic amino acid, Cys corresponding to position 152 of SEQ ID NO:1, amino acid affecting isoelectric point of the wild-type or variant adiponectin, amino acid affecting beta sheet formation, helix capping, or dipole interactions, or a combination thereof, wherein the adiponectin variants exhibit improved stability, solubility or soluble expression, expression yield, the ability to induce phosphorylation of AMPK, or a combination thereof, as compared to the corresponding wild-type adiponectins.
摘要翻译:在具有预定疏水性,预定极性,预定静电位,Met,芳香族氨基酸,对应于SEQ ID NO:1的位置152的Cys,影响等电点的氨基酸的位置,包含与相应的野生型脂连蛋白的一个或多个氨基酸修饰的脂连蛋白变体 野生型或变体脂联素的点,影响β片形成的氨基酸,螺旋封端或偶极相互作用或其组合,其中脂联素变体表现出改善的稳定性,溶解性或可溶性表达,表达产量,诱导磷酸化的能力 的AMPK,或其组合,与相应的野生型脂连蛋白相比。